Evidence map›Paper›PMID 22359489›Full record

ArticlePLoS computational biology2012

A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability.

Shingo Iwami, Hiroshi Haeno, Franziska Michor

Abstract read
In one paragraph

Article in PLoS computational biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. A mathematical model of pre-diagnostic glioma growth.Journal of theoretical biology · 2015
    Article
  4. Turning ecology and evolution against cancer.Nature reviews. Cancer · 2014
    Review
  5. Review
  6. Article
  7. Article
  8. Bioinformatics for cancer immunology and immunotherapy.Cancer immunology, immunotherapy : CII · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shingo IwamiPRESTO, Japan Science and Technology Agency, Graduate School of Mathematical Sciences, The University of Tokyo, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Hiroshi Haeno
Franziska Michor

Funding

The Cell-Of-Origin of Human CancersU54CA143798 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI MICHOR, FRANZISKA · 2009 to 2014
$11.2M
NCI NIH HHS U54 CA143798NCI NIH HHS U54CA143798
6 · The paper itself

Abstract

The human immune system functions to provide continuous body-wide surveillance to detect and eliminate foreign agents such as bacteria and viruses as well as the body's own cells that undergo malignant transformation. To counteract this surveillance, tumor cells evolve mechanisms to evade elimination by the immune system; this tumor immunoescape leads to continuous tumor expansion, albeit potentially with a different composition of the tumor cell population ("immunoediting"). Tumor immunoescape and immunoediting are products of an evolutionary process and are hence driven by mutation and selection. Higher mutation rates allow cells to more rapidly acquire new phenotypes that help evade the immune system, but also harbor the risk of an inability to maintain essential genome structure and functions, thereby leading to an error catastrophe. In this paper, we designed a novel mathematical framework, based upon the quasispecies model, to study the effects of tumor immunoediting and the evolution of (epi)genetic instability on the abundance of tumor and immune system cells. We found that there exists an optimum number of tumor variants and an optimum magnitude of mutation rates that maximize tumor progression despite an active immune response. Our findings provide insights into the dynamics of tumorigenesis during immune system attacks and help guide the choice of treatment strategies that best inhibit diverse tumor cell populations.

Indexed as

Epigenesis, GeneticGenome, HumanAnimalsCell Transformation, NeoplasticComputational BiologyDisease ProgressionHumansImmune SystemModels, StatisticalModels, TheoreticalMutationNeoplasmsPhenotype

Identifiers

PMID22359489
PMCPMC3280962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.